Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 15, 2023
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
Sumant Kulkarni Maintained (BTAI) at Strong Buy with Decreased Target to $20 on, Aug 15th, 2023
Sumant Kulkarni of Canaccord Genuity, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $76 to $20 on, Aug 15th, 2023.
Sumant has made no other calls on BTAI in the last 4 months.
There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 1 agrees with Sumant's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023
This is the rating of the analyst that currently disagrees with Sumant
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Monday, July 3rd, 2023
